Heart Safety Study of Ondansetron in Children Receiving Chemotherapy

Withdrawn before enrolling · Phase 4

Conditions studied: Malignant Childhood Neoplasm

In brief

We will study the effects of ondansetron on measurements of electrical activity in the heart to make sure doses we are using to prevent nausea and vomiting in children receiving chemotherapy are safe.

Key facts

Study ID

NCT01896440

Run by

University of Oklahoma

People needed

0

Starts

2013-10-01

Expected to finish

2013-10-01

Last updated by the study team

2013-10-08

Who can join

Age: 1 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 6 months to 18 years
• Diagnosis of cancer and receiving 2 identical cycles of chemotherapy within 2 months of each other

You may not qualify if…

• History of cardiac conduction anomalies, myocardial infarction, structural heart abnormalities (even if repaired)
• Pregnant or of child-bearing age and unwilling to take a pregnancy test
• Potassium or calcium outside of reference range at screening
• Liver enzymes (AST/ALT) or bilirubin >/= 2 x the upper limit of normal at screening

Where it is running

• University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.